Addition of a single short-acting insulin bolus to basal insulin-supported oral therapy: a systematic review of data on the basal-plus regimen
Open Access
- 1 October 2019
- journal article
- review article
- Published by BMJ in BMJ Open Diabetes Research & Care
- Vol. 7 (1) , e000679
Abstract
We summarize here clinical and trial data on a once-daily administration of a single bolus to the meal with the largest expected postprandial glucose excursion (basal-plus), and comment on its clinical utility in the treatment of type 2 diabetes. A PubMed search of data published until September 2018 was taken into consideration and PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines were followed. Eighteen reports representing 15 studies were identified (age: 18–80 years; 50–890 patients; follow-up: 8 days to 60 weeks). Data suggest basal-plus is efficacious for improving glycemic control, with a low incidence of (severe) hypoglycemia and minor increases in bodyweight. The timing of short-acting insulin administration and use of different monitoring/titration approaches appear to have minimal impact. When compared with premixed insulin, basal-plus results in largely comparable outcomes. Compared with basal-bolus, it may result in non-inferior glycemic improvements with less weight gain, less hypoglycemia and fewer daily injections. A basal insulin/glucagon-like peptide-1 receptor agonist fixed ratio combination may offer several advantages over the basal-plus regimen, at the cost of gastrointestinal side effects. We conclude that the stepwise introduction of short-acting insulin via the basal-plus strategy represents a viable alternative to a full basal-bolus regimen and may help to overcome barriers associated with multiple injections and anticipated complexity of the insulin regimen.Keywords
Funding Information
- Sanofi Aventis Deutschland GmbH
This publication has 49 references indexed in Scilit:
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4)Diabetes Care, 2012
- Glycemic Effects of Once-a-Day Rapid-Acting Insulin Analogue Addition on a Basal Insulin Analogue in Korean Subjects with Poorly Controlled Type 2 Diabetes MellitusDiabetes & Metabolism Journal, 2012
- Optimizing Insulin Glargine Plus One Injection of Insulin Glulisine in Type 2 Diabetes in the ELEONOR StudyDiabetes Care, 2011
- Effects of initiation and titration of a single pre‐prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6‐month ‘proof‐of‐concept' studyDiabetes, Obesity and Metabolism, 2011
- Modeling the lifetime costs of insulin glargine and insulin detemir in type 1 and type 2 diabetes patients in Canada: a meta-analysis and a cost-minimization analysisJournal of Medical Economics, 2011
- Algorithm for the introduction of rapid‐acting insulin analogues in patients with type 2 diabetes on basal insulin therapyPractical Diabetes International, 2009
- Exenatide-Associated Ischemic Renal FailureDiabetes Care, 2009
- Normal Glucose Values Are Associated With a Lower Risk of Mortality in Hospitalized PatientsDiabetes Care, 2008
- Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single‐dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugsDiabetes, Obesity and Metabolism, 2008
- Utilization of the PICO framework to improve searching PubMed for clinical questionsBMC Medical Informatics and Decision Making, 2007